DNA–gadolinium–gold nanoparticles for in vivo T1 MR imaging of transplanted human neural stem cells  by Nicholls, Francesca J. et al.
lable at ScienceDirect
Biomaterials 77 (2016) 291e306Contents lists avaiBiomaterials
journal homepage: www.elsevier .com/locate/biomater ia lsDNAegadoliniumegold nanoparticles for in vivo T1 MR imaging of
transplanted human neural stem cells
Francesca J. Nicholls a, b, d, 1, Matthew W. Rotz e, f, 1, Harmanvir Ghuman b, c,
Keith W. MacRenaris f, g, Thomas J. Meade e, f, **, Michel Modo a, b, c, *
a Department of Radiology, University of Pittsburgh, PA, USA
b McGowan Institute for Regenerative Medicine, University of Pittsburgh, PA, USA
c Department of Bioengineering, University of Pittsburgh, PA, USA
d Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK
e Departments of Chemistry, Neurobiology and Radiology, Northwestern University, Evanston, IL, USA
f Department of Molecular Biosciences, Northwestern University, Evanston, IL, USA
g Quantitative Bio-elemental Imaging Centre, Northwestern University, Evanston, IL, USAa r t i c l e i n f o
Article history:
Received 21 August 2015
Received in revised form
21 October 2015
Accepted 10 November 2015
Available online 14 November 2015
Keywords:
MRI
Gadolinium
Nanoparticles
Gold
Contrast agent
Neural stem cells
Cell transplantation
Gd-HPDO3A* Corresponding author. University of Pittsburgh, M
erative Medicine, 3025 East Carson St, Pittsburgh, 152
** Corresponding author. Northwestern University
Evanston, IL, 60208, USA.
E-mail addresses: tmeade@northwestern.edu (T.J. M
(M. Modo).
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.biomaterials.2015.11.021
0142-9612/© 2015 The Authors. Published by Elseviera b s t r a c t
The unambiguous imaging of transplanted cells remains a major challenge to understand their biological
function and therapeutic efﬁcacy. In vivo imaging of implanted cells is reliant on tagging these to
differentiate them from host tissue, such as the brain. We here characterize a gold nanoparticle conjugate
that is functionalized with modiﬁed deoxythymidine oligonucleotides bearing Gd(III) chelates and a red
ﬂuorescent Cy3 moiety to visualize in vivo transplanted human neural stem cells. This DNA-Gd@Au
nanoparticle (DNA-Gd@AuNP) exhibits an improved T1 relaxivity and excellent cell uptake. No signiﬁ-
cant effects of cell uptake have been found on essential cell functions. Although T1 relaxivity is atten-
uated within cells, it is sufﬁciently preserved to afford the in vivo detection of transplanted cells using an
optimized voxel size. In vivo MR images were corroborated by a post-mortem histological veriﬁcation of
DNA-Gd@AuNPs in transplanted cells. With 70% of cells being correctly identiﬁed using the DNA-Gd-
AuNPs indicates an overall reliable detection. Less than 1% of cells were false positive for DNA-
Gd@AuNPs, but a signiﬁcant number of 30% false negatives reveals a dramatic underestimation of
transplanted cells using this approach. DNA-Gd@AuNPs therefore offer new opportunities to visualize
transplanted cells unequivocally using T1 contrast and use cellular MRI as a tool to derive biologically
relevant information that allows us to understand how the survival and location of implanted cells
determines therapeutic efﬁcacy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The regional distribution of transplanted neural stem cells
(NSCs) inﬂuences their sphere of activity and correlates with the
degree of therapeutic efﬁcacy [1]. A greater understanding of the
positioning of transplanted NSCs could hence improve ourcGowan Institute for Regen-
03, USA.
, Department of Chemistry,
eade), modomm@upmc.edu
Ltd. This is an open access articletargeting of cell injections to areas crucial to their efﬁcacy. How-
ever, mapping the in vivo distribution of transplanted cells remains
amajor challenge [2,3]. In the context of intracerebral transplants, a
range of 1,000e400,000 cells needs to be detected at a high in vivo
spatial resolution (<64 nL voxel) using an unequivocal multi-voxel
signal that predominantly derives from transplanted cells with a
low risk of false positives (<5%, type I error) and negatives (<20%,
type II error) [2,4]. The selective visualization of transplanted cells
by magnetic resonance imaging, nevertheless, requires contrast-
inducing particles [3].
Iron oxide (magnetite/maghemite) particles yield a high relax-
ivity that affords single cell tracking [5]. However, potential
blooming artifacts due to air bubbles and small hemorrhage on T2-
and T2*-weighted magnetic resonance images (MRI), in addition tounder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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equivocal interpretation of in vivo cell distribution in the brain [2].
An unequivocal signal can potentially be produced by T1 agents,
such as Mn(II) and Gd(III). Mn(II) agents are easily taken-up into
cells by substituting for Ca2þ ions. Although this affords the T1
detection of labeled cells [7e10], unchelated manganese which is
required for cellular uptake is known to exert cytotoxic effects [11].
Cellular labeling with monomeric gadolinium agents taken-up
through endocytosis typically quenches the T1 contrast enhance-
ment due to endosomal sequestration, but electroporation of the
agent into the cytoplasm preserves the T1 signal [12]. Several re-
ports indicate the possibility to visualize cells using this MRI
approach [13e18]. However, positive identiﬁcation of a T1 signal
in vivo requires evidence that the agent is localized intracellularly in
the transplanted cells (as assessed by an independent marker). This
is necessary to prevent false identiﬁcation of contrast agent inad-
vertently injected, bound to the outside of the cell membrane or
exocytosed from the transplanted cells.
The thermodynamic and kinetic stability of chelated Gd(III)
compounds is also essential to avoid cytotoxicity, which can be
delayed or avoided if Gd(III) can be contained within the chelate.
Macrocylic ligands based on 1,4,7,10-tetraazacyclododecane-
1,4,7,10-teraacetic acid (DOTA) exhibit similar thermodynamic
stabilities compared to those of the linear diethylene triamine
(DTPA) ligand [19], but are more kinetically stable, and are thus a
more favorable chelate for Gd(III)-based agents [20,21]. Immobili-
zation of Gd(III) complexes onto macromolecules or proteins that
restrict the motion of Gd(III) chelates can improve the relaxivity
compared to monomeric Gd(III)-agents [22]. Intracellular concen-
tration (and hence cellular relaxivity) could be further improved by
using this strategy [23].
Achieving a high cellular relaxivity requires an optimized
nanoconjugate Gd(III) contrast agent with a high thermostability
that affords an efﬁcient cell uptake. In recent work by Song et al.
[24], Gd(III) labeled DNA gold nanoparticle conjugates (DNA-
Gd@AuNP) were shown to be a biocompatible and highly effective
platform for cell labeling of HeLa and NIH 3T3 cancer cells [25].
Importantly, the DNA-Gd@AuNP showed an excellent pH stability
and inertness towards transmetallation [26], with attached oligo-
nucleotides affording an efﬁcient cell uptake through the CXCR7
scavenger receptor and peri-nuclear localization [27]. Especially in
serum-free cultures (as used for human neural stem cells), these
oligonucleotides are efﬁcient trans-membrane localization tools.
There is further evidence that AuNP in the proximity of Gd(III)-
agents serve as “nanoampliﬁers” to increase MR relaxivity [28].
Multimodal Gd(III)-conjugated AuNP have been used to visu-
alize pancreatic islets [29] and for targeting tumors [30e32] using
MRI, but also show potential as theranostic agents for photo-
thermal therapy to ablate cancers [33]. We here characterize the
DNA-Gd@AuNPs to visualize the distribution of human neural stem
cells using MRI by performing in vitro assays to determine cell
uptake, potential cytotoxicity and cellular relaxivity. Optimal im-
aging parameters are deﬁned in vitro and applied in vivo to visualize
transplanted cells by T1-weighted MRI with validation using ﬂuo-
rescent immunohistochemistry.
2. Methods
2.1. Synthesis and quality assurance of DNA-Gd@AuNP
nanoparticles
2.1.1. Gold nanoparticle synthesis
Citrate stabilized AuNPs were synthesized by reduction of
HAuCl4 by sodium citrate in aqueous media. Speciﬁcally, in an acid
washed two necked round bottom ﬂask 0.197 g of gold(III) chloridewas added to 0.496 L of water while stirring. The solution was
brought to reﬂux and 0.574 g of trisodium citrate dihydrade pre-
dissolved in 0.004 L of water was added. The solution is left to
reﬂux for 30 min, cooled to room temperature, and ﬁltered [24,34].
2.1.2. Gd(III)-labeled oligonucleotide synthesis
Oligonucleotides were synthesized on solid phase CPGs by
standard techniques on a MerMade automated synthesizer. All
oligonucleotide synthesis reagents and protected 30-Thiol modiﬁer
CPGs were purchased from Glen Research (Sterling, Va). Specif-
ically, the synthesized oligonucleotide consisted of the sequence 3’
e S-S-TTT-TTT-TTT-T*TT-T*TT-T*TT-T*TT-T*TTeCy3 50, where C6
amino modiﬁer dT modiﬁed bases that are indicated by T*. Cy3 is
added as the ﬁnal base by the use of a Cy3 phosphoramidite
coupled under standard conditions. Oligonucelotides were depro-
tected from the solid phase using AMA conditions [(1:1 methyl-
amine:ammonium hydroxide (sat.)] for one hour. Deprotected DNA
was puriﬁed from failed sequences by reversed phase high pressure
liquid chromatography (HPLC) using a C18 column with 30 mM
triethylammonium acetate buffer and a linear gradient of acetoni-
trile on a Varian ProStar 500 instrument. The eluted product was
lyophilized and characterized by matrix assisted laser desorption
ionization mass spectrometry (MS-MALDI) using a Bruker AutoFlex
III spectrometer. Successful DNA synthesis was conﬁrmed, (m/z)
observed: 8762.1, calculated: 8760.7 [MH]-. Azide functionality
was subsequently added by the solution phase coupling of azido-
butyrate NHS ester (Glen Research) in the presence of aqueous
carbonate. Complete conversion of pendant amines to azides was
again conﬁrmed by MALDI, and 5x azide DNAwas puriﬁed by HPLC
and lyophilized, (m/z) observed: 9318.2, calculated: 9326.3 [MH]-
[34].
The inorganic Gd(III) complex was synthesised using standard
organic chemistry techniques using a previously reported proce-
dure [34]. Brieﬂy, a primary alkyne bearing linker armwas designed
to bear an a,b-unsaturated ketone. This small molecule was
reﬂuxed in acetonitrile and potassium carbonate for four days to
complete the 1,4-conjugate addition to the tert-butyl protected
DO3A macrocyclic ligand. After conjugation, the chelate is depro-
tected in triﬂouroacetic acid, metalated and puriﬁed by HPLC.
Lyophilized product was characterized by electrospray ionization
mass spectrometry (ESI-MS) on a Varian 1200L single-quadrupole
mass spectrometer, (m/z) observed: 609.2, calculated: 610.7 [M þ
H]þ.
Conjugation of the Gd(III) to the azide modiﬁed DNA was per-
formed using Cu(I)-catalyzed 1,3 dipolar cycloaddition (click)
chemistry (Fig. 1A). Speciﬁcally, azide modiﬁed DNA and alkyne-
bearing Gd(III) complex was dissolved in 1.5 M triethylammo-
nium acetate buffer, to which was added Cu(II) Sulfate, tris-
hydroxypropyl triazolylamine (used for stabilization of the Cu(I)
oxidation state, and to act as a sacriﬁcial reagent against oxidative
cleavage of the DNA backbone), and sodium ascorbate. Upon
complete reaction product, DNA was puriﬁed by HPLC as prior and
ﬁnal characterization was performed using MALDI (m/z) observed:
12374.3, calculated: 12372.3 [MH]-
2.1.3. DNA-Gd@AuNP synthesis
Particle conjugation was carried out by deprotection of the 30
thiol protecting group by chemical exchange using dithiothreitol,
and puriﬁed from this mixture using G25 sephadex (NAP 5, GE Life
Sciences). Puriﬁed DNA was mixed with citrate capped gold
nanoparticles in a ratio of 1 OD DNA/mL AuNP, followed by salt-
aging (Fig. 1A), a technique which adds successive increases in
salt conditions. The salt concentration was incrementally increased
up to 600 mM using ﬁve aliquots of 5M NaCl over six hours, at
which time the particles were left to stir for 48 h. Upon completion
Fig. 1. DNA-Gd@AuNP synthesis and stability. Particles consist of a gold nanoparticle core loaded with DNA to which the Gd-HPDO3A and Cy3 moieties are attached (A).
Transmission electron microscopy (TEM) of conjugated DNA-Gd@Au nanoparticles for size determination (B). Particles retain their relaxivity properties at 1.41 T over more than 2
weeks (C). There is a small amount of Gd(III) loss at 37 C, amounting to <5% of total Gd(III) over 2 weeks. However, loss is negligible (<0.4%) when particles are stored at 4 C (D).
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purify excess Gd-DNA and concentrate the particles for subsequent
studies. Particle loading was assessed by inductively coupled
plasma-mass spectroscopy (ICP-MS) analysis of fully synthesized
particles by observation of the ratio of Gd(III) to Au(III). This was
done using either a computer-controlled (Plasmalab software)
Thermo (Thermo Fisher Scientiﬁc) PQ ExCell ICP-MS equipped with
a CETAC 500 autosampler or a computer-controlled (Plasmalab
software) Thermo X series II ICP-MS equipped with an ESI (Omaha)
SC-2 autosampler. Each samplewas acquired using 1 survey run (10
sweeps) and 3 main (peak jumping) runs (100 sweeps). The iso-
topes selected were 197Au and 156,157Gd. 115In, 165Ho, and 209Bi
served as internal standards for data interpolation and instrument
stability.
2.1.4. Dynamic light scattering (DLS)
DLS was performed using a Malvern Zetasizer using the
number average analysis of multiple consecutive measurements.
Speciﬁcally, data was collected using an Au refractive index of0.470, absorbance of 0.100, and a viscosity of 0.8872. All mea-
surements were performed in H2O at 25 C. Herein, we report the
number of average measurements of particle size, because in-
tensity measurements showed a slightly larger hydrodynamic
size and broader distribution (skewed non-linearly by increased
scattering of a few larger particles, whose presence were not
even observed during TEM analysis). Each analysis consisted of
three separate measurements, each of which utilized 16 indi-
vidual samplings in order to estimate hydrodynamic radius and
standard deviation. MarkeHouwink parameters were used in the
mathematical model for determination of size and standard de-
viation. These measurements were primarily used to conﬁrm
DNA conjugation and potential aggregation of individual parti-
cles. Further conﬁrmation was achieved using the plasmon
resonance peak by UV/Vis spectroscopy (see below).
2.1.5. Transmission electron microscopy (TEM)
Nanoparticle characterization was performed on JEOL 1230 and
Hitachi HD7700 TEMs using particles dried onto copper grids (Ted
Table 1
MR imaging parameters (relaxation time ¼ TR; echo time ¼ TE, ﬁeld of view¼ FOV).
TR (s) TE (ms) Averages FOV (mm)
In vitro Solution T1 map 10.4 40 1 45  30
T1w 0.5 2.02 1
T2 map 5 15e480 1
T2w 2 27.87 1
Cells T1 map 12.2 40 1 45  25
T2 map 3 15e480 1
T2w 3 32.74 1
Ex vivo T1 map 15.4 40 1 30  30
T2 map 6 7.2e229 2
T2w 6.1 70.78 8
In vivo T1 map 10.4 40 1 30  30
T1w 0.5 2.73 6
F.J. Nicholls et al. / Biomaterials 77 (2016) 291e306294Pella, Inc.). Particle size analysis was performed using TEM images
and ImageJ software for measurement and statistical analysis of
100 individual particles. Error reported represents the standard
deviation of the mean.
2.1.6. Ultraviolet/visible (UV/Vis) light spectrophotometry
UV/Vis spectra were acquired on a HP8453-1 spectrophotom-
eter (Agilent). Colloidal stability of prefunctionalized citrate-
capped gold nanoparticles and post-functionalized DNA-
Gd@AuNP was conﬁrmed by measuring the plasmon resonance
absorbance at 523 nm for citrate stabilized particles and 519 nm
for DNA conjugates [35].
2.1.7. Shelf-life stability
Solutions of concentrated DNA-Gd@AuNPs were diluted into
duplicate tubes of Hank's Balanced Saline Solution (HBSS) at buffer
strengths of 0.1x, 0.5x and 1x. The particles were stored at 4 C for
two weeks. Every other day, DNA-Gd@AuNPs were centrifuged
and sampled for supernatant Gd(III) concentration. Data was
processed such that the Gd(III) observed in the supernatant was
quantiﬁed as a percentage of the original Gd(III) concentrated by
ICP-MS (see 2.4). A subsequent trial was performed in 0.1x HBSS at
55 nM of nanoconjugates per tube and stored either at 4 C, and a
second tube of the same concentration was incubated for the same
period at 37 C. ICP-MS was used to quantify the initial particle
concentrations, including total Gd(III) content per tube. Particles
were stored for 24 h, at which time they were vortexed and
centrifuged (30 min at 4 C, 21,000 g). A sample of the supernatant
was removed (containing no AuNPs), which was analyzed for
Gd(III) content. The Gd(III) content measured was normalized to
the initial Gd(III) concentration of each tube, and quantiﬁed as
percentage of Gd(III) lost from the particle surface into the sur-
rounding solution, as indicated above. This process was repeated
in 24 h increments for a period of two weeks. In parallel with shelf
life stability experiments, a separate aliquot of particles was
measured for r1 and r2 relaxivities (see below) on the ﬁrst day
after conjugation. Other than the particles used for ICP analysis,
particles were recovered and re-concentrated after the measure-
ment of relaxivity and then placed back into storage at 4 C. This
process was repeated on days 8 and 17.
2.1.8. Nanoparticles relaxivity in solution (Northwestern)
A stock of DNA-Gd@AuNP conjugates was serially diluted for a
concentrated stock for a total of ﬁve solutions. 250 mL of each
concentration was warmed to 37 C and placed into a Bruker
minispec mq60 NMR spectrometer (60 MHz, 1.41 T) for measure-
ment of T1 and T2 relaxation times (in s). Data was collected using
an inversion recovery pulse sequence, with a 20 s repetition time
and 10 data points (average of 4 measurements per point). The
remaining volumes of each solutionwere utilized for ICP analysis of
Gd(III). The inverse of the longitudinal relaxation time was calcu-
lated to obtain the relaxation rate (R1 ¼ 1/T1, in s1) which was
plotted against the Gd(III) concentration (mM). By applying a linear
ﬁt to this data, the slope generated is reported as the relaxivity (r1)
of the agent (inmM1 s1). Linear regressions were ﬁttedwith R2 of
>0.99. Relaxivity indicates changes in relaxation rate as a function
of concentration [36].
2.1.9. Nanoparticles relaxivity in solution (Pittsburgh)
To ensure that the MR properties of the DNA-Gd@AuNP were
not compromised during shipping, their relaxivity was measured
again within 2 days of their arrival. To evaluate a dose-dependent
effect on the MR signal (R1 and R2) different concentrations (0.01,
0.02, 0.05, 0.09, 0.18 mM) were arrayed in phosphate buffered
saline (PBS) in 0.1 mL PCR tubes (Axygen) placed in 6% gelatin andcontrasted with a commercially available standard of monomeric
Gd-HPDO3A (ProHance, Bracco Imaging). Solution phantoms were
placed in a 9.4 T (400 MHz) horizontal bore system equipped with
VnmrJ 3.1 software (Varian). For transmission and acquisition, a
custom made volumetric birdcage quadrature coil (Virtumed LLC),
achieving a radiofrequency (RF) power input of up to 55 mT/5 s
with an internal diameter of 36 mm and effective length of 25 mm
was used. For R1 (1/T1) measurements, a fast spin echo (FSE)
sequence with a global inversion recovery (IR) with inversion time
(Ti) values of 0.01, 2, 4, 6, 8, 10 and 10.2 s (Table 1 for details of all
imaging acquisition parameters) was used, whereas a multi-slice
multi-echo (MSME) sequence provided measurements for R2 (1/
T2). All scanning was performed with the phantom at 37 C. From
individual images, T1 and T2 maps were created in VNMRJ with
the inverse of these (R1 and R2) being computed in Matlab v8.1.
(Mathworks). A linear regression was performed to determine the
relaxivity (r1 and r2) of the agent as expressed in mM1s1.2.2. Cell culturing
The human striatal neural stem cell (NSC) line STROC05 (kindly
provided by ReNeuron, UK) were cultured and passaged, as previ-
ously described in detail [37,38]. In brief, STROC05 NSCs are
conditionally immortalized using cMyc-ERTAM under the control of
4-hydroxytamoxifen (100 nM; Sigma). In the absence of 4-
hydroxytamoxifen NSCs will cease proliferation and undergo dif-
ferentiation. NSCs were expanded on laminin (10 mg/mL) coated
ﬂasks until they reached a 70e80% conﬂuency. Recombinant hu-
man basic ﬁbroblast growth factor (bFGF; 10 ng/mL; PeproTech)
and epidermal growth factor (EGF; 20 ng/mL; PeproTech) were
used asmitogens. All culturing was performedwithout the addition
of antibiotics at 37 C in 5% CO2.2.3. Cell labeling
STROC05 were labeled with DNA-Gd@AuNP in vitro under
proliferative conditions. For this, cells were grown to a conﬂuency
of ~50% and DNA-Gd@AuNPs were added to fresh medium at
different concentrations (0, 0.02, 0.2, 2 or 20 nM). Additional con-
centrations (50, 100, 200 nM) of DNA-Gd@AuNP were also tested,
but there was signiﬁcant cytotoxicity and these were hence
excluded from further analysis (Supplementary Fig. 1). Cells were
incubated for 24 h prior to being washed 3x with HBSS (Gibco) and
harvested using Accutase (Sigma) before being used for in vitro
assays.
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2.4.1. Agent uptake measurements based on ﬂuorescence
The DNA-Gd@AuNP contains a Cy3moiety that affords detection
of the nanoconjugates using ﬂuorescence microscopy. For the
different concentrations, cells were incubated for 24 h prior to
being washed 3x with HBSS and ﬁxed for 15 min using 4% para-
formaldehyde. Coverslips were stored in 24 well plates with PBS.
For analysis, cells were mounted using Vectashield for ﬂuorescence
with DAPI (Vector Laboratories). For each of the 3 batches of DNA-
Gd@AuNPs, 3 technical replicates were performed for 3 biological
replicates.
Using a M2microscope (Zeiss) with an X-Cite Series 120Q (Exfo)
illumination interfaced with a high sensitivity monochrome cam-
era Axiocam MrM (Zeiss) and StereoInvestigator version 11.07
software (MBF Bioscience), images in 5 ﬁelds-of-view per coverslip
were acquired in the red channel (range 525e575 nm range), as
well as the blue channel (range 335e383 nm) for DAPI. Image
acquisition settings were maintained for all images. Cy3 signal in-
tensity in acquired images was quantiﬁed using Matlab v8.1.
(Mathworks). To obtain a measure of relative ﬂuorescence units
(RFU) per cell, the signal intensity was divided by the number of
cells (based on manual counting of DAPIþ nuclei) contained within
each image.2.4.2. Survival and proliferation
To determine if cell labeling at different concentrations affects
the survival of NSCs or their proliferation, the number of DAPI
positive cells present at day 0 (i.e. 24 hrs post-labeling) and day 7
were counted. For this, cells were grown under differentiation
conditions (i.e. withdrawal of 4-hydroxytamoxifen, bFGF, and EGF).
As STROC05 are adherent cells, once their health is compromised
they detach. Hence counting the number of attached cells is a
measure of survival.
Nevertheless, survival at 7 days can also be affected by the
continued proliferation of NSCs. Tomeasure a potential effect of cell
labeling on proliferation, cells were also stained with a Ki67 anti-
body, which indicates all active phases of the cell cycle (i.e. G1, S, G2
and mitosis) at day 0 and day 7 post-labeling. For immunocyto-
chemistry, ﬁxed cells were washed 3x with PBS prior to the
application of the primary rabbit antibody against Ki67 (1:500,
Abcam, ab15580). After overnight incubation at room temperature
(21 C), the primary antibody was removed and cells were washed
3x in PBS prior to application of the secondary goat anti-rabbit
Alexa 488 (1:500, Molecular Probes, A-11034) for 1 h. Cells were
washed 3x in PBS and mounted with Vectashield for ﬂuorescence
with DAPI. The number of Ki67þ cells were counted and expressed
as percentage in relation to the total number of DAPIþ cells.2.4.3. Cell differentiation
To assay potential effects on NSC differentiation into appropriate
cell phenotypes, i.e. neurons and astrocytes, or lineage-speciﬁc
toxicity, cells were allowed to differentiate for 7 days [38]. Only
the 20 nM condition was tested, as this was the highest concen-
tration without evidence of detrimental effects. To measure a po-
tential effect on cell differentiation, immunocytochemistry (as
described above) was performed on ﬁxed cells to measure the
number of neurons, as indicated by staining with a rabbit anti-
beIIIeTubulin (Tuj, 1:500, Abcam, ab18207) antibody, and astro-
cytes, as revealed by mouse anti-Glial Fibrillary Acidic protein
(GFAP, 1:3000, Sigma, G3893) antibody on day 0 and day 7. To
indicate a % change due to cell labeling, a comparison to unlabeled
cells was performed.2.5. ICP-MS analysis of labeled cells
The Gold and Gadolinium content of cells incubated with
different NP concentrations for 24 h was determined using ICP-MS.
Cells were collected in 0.1 mL Accutase. A suspension of 5 mL was
digested with 120 mL of nitric acid (70%, Sigma) and concentrated
hydrochloric acid (37%, Sigma). To assay for Gd(III), samples were
diluted to a total volume of 3 mL with Nanopure water to a ﬁnal
combined acid concentration of 2% (v/v) nitric and 2% (v/v) hy-
drochloric acids. To probe Au(III) content, samples were diluted to a
total of 10 mL with Nanopure water with the same ﬁnal concen-
trations of acid as with Gd(III) samples.
2.6. Cellular relaxivity
Due to the potential T1 quenching of Gd(III)-agents on uptake
into cells [12], it is essential to establish if a T1 effect is preserved.
For cell pellet phantoms, cells were washed three times in HBSS
after cell labeling with 20 nM for 24 h prior to being harvested
using Accutase and pelleted in a 0.1 mL PCR tube. NSCs labeled with
Gd-HPDO3A (20 nM incubation for 24 h), as well as unlabeled cells,
served as a control. For cell suspension phantoms, cells were re-
suspended in DMEM/F12 for counting on a hematocytometer.
Counted cells were suspended at 10  103, 50  103, 10  103,
150  104 and 200  104 cells/mL in a ﬁnal concentration of 6%
gelatin.
To calculate a T1 map, images were acquired on a 9.4 T hori-
zontal MRI scanner using a sequence employing global Inversion
Recovery (IR) with a fast spin echo (FSE) readout (Table 1) with a T1
map being calculated inMatlab. T2 maps were acquired usingMulti
Slice Multi Echo (MSME) with 32 echoes, where TE was varied
between each echo by 15 ms (Table 1). T2-weighted images were
acquired using Fast Spin Echo Multi Slice (FSEMS: Table 1). All ex-
periments were conducted at 37 C.
The Gd(III) concentration of each phantom was calculated from
the known cell density and cell uptake of DNA-Gd@AuNP. Plotting
of the phantom Gd(III) concentration against R1 (1/T1) using a
linear ﬁt speciﬁed the relaxivity (r1) in mM1s1. Cellular relaxivity
(r1 cellular) was measured by calculating the percentage change in
relaxivity between unlabeled and labeled cells, as previously
described [39]. Based on this, an estimatewasmade to calculate the
minimum number of cells needed for a >5% signal change in T1.
Signal-to-noise (SNR) was calculated by dividing the mean
signal from an ROI on the cell pellet by the mean signal outside of
the sample, deﬁned as noise. Contrast was deﬁned as the mean
signal of the pellet of labeled cells minus the mean signal of the
unlabeled pellet [40]. These signal measurements were taken in the
center of the pellet to avoid partial volume effect. To determine the
inﬂuence of partial volume effects on detectability of labeled cells,
measurements from the center of the pellet were compared to
mean signal measurements that encompassed the whole pellet, i.e.
center þ corona (deﬁned as the outmost edge visibly distinguish-
able from the gel). As partial volume effects are highly dependent
on voxel size, samples were acquired at different voxel volumes (4,
8, 17, 31, 69, 112, 275 nL). The slice thickness was kept constant at
0.5 mm, whilst the matrix size within the 45  25 mm FOV was
varied (64x32, 96x48, 128x64, 192x96, 256x128, 384x192 and
512x256).
2.7. Cell transplantation
All in vivo procedures complied with the Institutional Animal
Care and Use Committee (IACUC), as well as NIH guidelines. On the
day of implantation, labeled (20 nM of DNA-Gd@AuNP for 24 h) and
unlabeled cells were suspended at 125  103 cells/mL in 4 mg/mL
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Badylak, University of Pittsburgh) to promote retention within the
brain after transplantation [41]. Viability of cells in this preparation
was >85%. Animals were anesthetized using isoﬂurane (4% induc-
tion, 2% maintenance) in medical air and placed in a stereotactic
frame (Kopf). A 10 mL Hamilton syringe containing the cell sus-
pension was inserted into the injection site. Using a micro pump
(Micro4, WPI) at a speed of 1 mL/min, one animal received 3
different volumes of labeled (left hemisphere) and unlabeled (right
hemisphere) to yield a total of 2.50  105, 6.25  105 and
10  105 cells for an ex vivo imaging designed to determine optimal
detection parameters. Using this information for an in vivo imaging
experiment, a total volume of 5 mL (total of 6.25  105 cells) of cells
was injected in a single deposit of unlabeled (right hemisphere) and
DNA-Gd@AuNP-labeled cells (left hemisphere) (n ¼ 3). After
completion, the needle was left in place for two minutes before
being retracted. Bonewaxwas used to ﬁll the skull defect caused by
the drill holes. Animals were sutured and given topical analgesic
cream (2.5% Lidocaine and 2.5% Prilocaine, Sandoz) and Buprenex
(0.05 mg/kg i.p.; Henry Schein).
2.8. Ex vivo MR imaging
To determine an appropriate voxel size for in vivo imaging,
images for T1 maps were acquired using global Inversion Recovery
(IR) with fast spin echo (FSE) readout, whereas T2 maps used a
MSME sequence (Table 1) on a 9.4 T horizontal MRI scanner. The
matrix size was arrayed (48x48, 64x64, 96x96, 128x128, 192x192
and 256x256) within a constant slice thickness of 0.5 mm and FOV
of 30  30 mm to yield voxel volumes volumes of 7, 12, 28, 49, 110,
and 195 nL.
2.9. In vivo MR imaging
The day following cell implantation, animals underwent MR
imaging (9.4 T). For this, animals were anesthetized using iso-
ﬂuorane (4% induction, 1.5% maintenance) in medical air, while
their physiology (temperature, respiratory rate) was monitored
using a MP150 Biopac system interfaced with AcqKnowledge v4.1
software (Biopac Systems Inc.). Based on the ex vivo voxel size and
cell concentration experiment, T1eweighted MRI images were ac-
quired using a Gradient Echo Multi Slice sequence (Table 1).
2.10. Immunohistochemistry
Immediately after imaging, animals were sacriﬁced using Fatal
Plus (Henry Schein) and underwent transcardial perfusion-ﬁxation
using 4% Paraformaldehyde (PFA, Electron Microscopy Sciences).
Brains were then removed and placed in 4% PFA overnight to ensure
complete ﬁxation. Brains were cryoprotected in 30% sucrose for
3e4 days before being sectioned using a cryostat (Leica) at 40 mm
thickness. Sections were stored at 20 C.
For immunohistochemistry, sections were washed 3x with PBS
before being incubated in blocking solution (0.5% Triton X100, 10%
Normal Goat Serum in PBS) for 1 h at room temperature. The pri-
mary antibody, mouse anti-human nuclei antigen (HNA, 1:400,
Millipore, MAB1281) was diluted in blocking solution and incu-
bated overnight at 4 C. Sections were washed 3x PBS before
exposure to the appropriate anti-mouse AlexaFluor488 secondary
antibody (1:500, Life Technologies) for 1 h at room temperature.
After 3x PBS washes,1 mg/mL Hoechst33342 (Sigma) was applied as
a nuclear counterstain and coverslipped using Vectashield for
ﬂuorescence mounting medium. Images were acquired using the
same set-up as described above. Whole slice images were acquired
using the Virtual Tissue software module in StereoInvestigator(MBF). The ﬁrst, last and centre sections containing HNAþ cells
were chosen as a representative coverage of the graft with
Hoechstþ, HNAþ and/or DNA-Gd@AuNPs counted using FIJI image
analysis software (NIH). Cells (Hoechstþ) were categorized as
“correctly identiﬁed” if both HNA and DNA-Gd@AuNPs were pre-
sent, as a “false negative” cells were deﬁned as HNAþwithout DNA-
Gd@AuNPs, whereas “false positive” cells contained DNA-
Gd@AuNPs but were HNA-.
2.11. Statistical analyses
Statistical analysis of cell counts and measurements were per-
formed on mean values using one- or two-way analysis of variance
(ANOVA) followed by Bonferroni post-hoc analysis using SPSS for
Mac v17 (IBM). Percentage change measures for lineage differen-
tiation were compared using two-tailed independent t-tests. A p
value of <0.05 was considered signiﬁcant. Prism v6 (GraphPad) was
used to plot data as means ± standard deviation, as well as to
calculate the linear regressions for relaxivity measures. Contour
maps were drawn in Minitab v17 (Minitab Inc).
3. Results
3.1. Characterization of synthesis and quality control of DNA-
Gd@AuNPs
An initial characterization of synthesized gold nanoparticles
(AuNPs) by TEM indicates a diameter of these of 15.3 ± 1.4 nm.
DNA-Gd(III) strands were synthesized bearing 5 Gd(III) chelates
and were puriﬁed by HPLC. Conjugation of these strands to AuNPs
was achieved efﬁciently using click chemistry. A characterization of
DNA-Gd@AuNPs sizewas performed using dynamic light scattering
indicating a hydrodynamic radius of 35 ± 0.7 nm of the nano-
conjugate. UV/Vis spectroscopy showed no change in the
maximum plasmon resonance wavelength for citrate stabilized
particles (523 nm) and DNA-modiﬁed particles (519 nm) after
functionalization, indicating good colloidal stability
(Supplementary Fig. 2). Particle loading was assessed by ICP-MS
analysis of fully synthesized particles by observation of the ratio
of Gd(III) to Au(III). By calculating the volume of the nanoparticles
using a geometric approximation, based on the observed size by
TEM (Fig. 1B), and applying the density of bulk gold, a particle
loading of 326 ± 44 Gd(III) molecules per AuNP was determined.
This Gd(III) loading corresponds to a particle loading of 65 ± 9 DNA
strands per particle.
3.2. DNA-Gd@AuNP stability and relaxivity
The stability of the nanoparticles is essential to ensure detection
of implanted cells. The relaxivity (r1 and r2) of DNA-Gd@AuNP was
hence measured in solution for 17 days (Fig. 1B). At 1.41 T, r1 was
stable at 14.6 mM1s1, as was r2 at 38.5 mM1s1 (measured at
37 C). Both measurements indicate a stable particle that produces
a robust effect on the MR signal. This was further reﬂected in the
minimal loss of Gd(III) from the nanoparticle construct (Fig. 1C). At
4 C, the cumulative loss of Gd(III) was <0.5%, although a greater
loss (<5%) was seen at 37 C over 17 days. These particles can
therefore be safely stored for at least 2 weeks without affecting
their stability or relaxivity during shipment at room temperature
(21 C).
As a further quality control procedure, after shipment of parti-
cles, relaxivity of nanoparticles in solutionwasmeasured again on a
9.4 T MRI at 21 C and contrasted with commercially available Gd-
HPDO3A (ProHance). Both R1 and R2 were measured for different
Gd(III) concentrations to afford a direct comparison as to potential
Fig. 2. MR relaxivity of DNA-Gd@AuNP nanoparticles. R1 and R2 maps of DNA-Gd@AuNP and Gd-HPDO3A were generated at 9.4 T (A). DNA-Gd@AuNP was shown to have 2.2x
the r1 molar relaxivity of Gd-HPDO3A (B) and 13x the r2 relaxivity (C). Expressing r1 relaxivity on a “per mole of particle” basis suggested that r1 was 830x higher in DNA-Gd@AuNP
(D).
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Indeed, the improvement in relaxivity was clearly evident espe-
cially at higher concentrations (Fig. 2A). This results in a higher
molar relaxivity for the DNA-Gd@AuNPs compared to Gd-HPDO3A,
with r1 values of 6.68 and 3.01 mM1s1 respectively (Fig. 2B). r2 is
also higher, at 53.5 compared to 4.11 mM1s1 (Fig. 2C). It is
important to note that this improvement in relaxivity is for each
Gd(III) molecule, rather than the polymeric AuNP construct. The r1
for each DNA-Gd@AuNP is 2548 mM1s1, a very dramatic ~830
fold improvement compared to monomeric Gd-HPDO3A (Fig. 2D).
Nanoparticle complexation therefore improves the relaxation
properties of Gd-HPDO3A by increasing the relaxivity of each
Gd(III) molecule, as well as by complexion into a polymeric
construct that can be used to efﬁciently label cells.
3.3. Labeling of neural stem cells
In order to achieve the most sensitive detection of implanted
NSCs, the intracellular concentration of Gd(III) must be maximized
without any detrimental effects on cells. Oligonucleotides facilitate
an efﬁcient cellular uptake with a dose-dependent uptake being
evidenced with increasing amounts of NPs. This was evident by
DNA-Gd@AuNPs being visible inside NSCs using the Cy3 moiety at
24 h (Fig. 3A). Even at 0.02 nM there was clear evidence of DNA-
Gd@AuNPs uptake (Fig. 3B), but at 20 nM a far more signiﬁcant
amount of DNA-Gd@AuNPs were present intracellularly (Fig. 3C).
Quantiﬁcation of uptake was performed using relative Cy3 ﬂuo-
rescence, as well as an absolute measurement using ICP-MS forGd(III). Both showed the same pattern of a dose-dependent uptake
(Fig. 3D). A 20 nM incubation resulted in >3 times the uptake of
2 nM, and ~25 times the uptake of 0.02 nM incubation, yielding an
intracellular Gd(III) concentration of ~55 mM. A persistent concern
in the use of nanotechnology is the potential variability between
batches of nanoparticles. However, three separately synthesized
batches of DNA-Gd@AuNPs resulted in a highly reproducible and
consistent uptake of NPs into cells (Fig. 3E). Nevertheless, the
Gd(III) loading of the different batches revealed noticeable varia-
tions (Batch 1 ¼ 248 Gd/NP; Batch 2 ¼ 345 Gd/NP; Batch 3 ¼ 350
Gd/NP). As intracellular Gd(III) concentration is determined by
DNA-Gd@AuNPs uptake, batches with lower Gd(III) loading result
in lower intracellular concentrations (Fig. 3F). Quality control of
DNA-Gd@AuNPs loading for each batch is hence important to
ensure an optimal cellular concentration of Gd(III).
3.4. Cellular effects of DNA-Gd@AuNPs
Although uptake of particles was efﬁcient, the effects of la-
beling on cellular function also require investigation in order to
avoid detriment to any potential therapeutic efﬁcacy of the cells.
Cell survival and proliferation are key measures to evaluate after
cell labeling (Day 0), as well as at Day 7 (Fig. 4A). The survival of
cells on Day 0 was only signiﬁcantly reduced with a 20 nM in-
cubation concentration (p < 0.05) (Fig. 4B). However, this was an
acute effect, as by Day 7 all incubation concentrations presented
a survival equivalent to the control condition where no nano-
particles were present. Batch-to-batch variability was also
Fig. 3. Intracellular uptake of DNA-Gd@AuNP nanoparticles. Cell Uptake of DNA-Gd@AuNPs at different concentrations is shown by the ﬂuorescent Cy3 moiety (red, A, scale
bar ¼ 200 mm). Fluorescence was visible even at the lowest concentration (B, scale bar ¼ 100 mm) and appeared to be localized to the cytoplasm (C). Cell uptake was measured by
ICP-MS and RFU per cell, which followed very similar patterns (D). Comparing three separate batches showed that particle uptake was highly consistent between batches (E), but
that the variability in Gd(III) loading resulted in variation in intracellular Gd(III) concentration (F). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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ferences were seen between batches (Fig. 4C). No effect of
nanoparticles on proliferation was evident at Day 0 or 7 (Fig. 4D).
A differentiation experiment investigating NSCs potential to
differentiate in astrocytes (GFAPþ cells) and neurons (beIIIe
Tubulinþ cells) (Fig. 4E), revealed no signiﬁcant effect of 20 nM
DNA-Gd@AuNP (Fig. 4F). Apart from a transient effect on cell
survival at day 0, 20 nM DNA-Gd@AuNP labeling therefore does
not affect the cell functions and provides a viable labeling
strategy to visualize NSCs using MRI.
3.5. Detecting labeled cells using MRI
To assess whether the achieved intracellular concentration of
Gd(III) was sufﬁcient for visualization of labeled cells using MRI,
cells incubated with 20 nM nanoparticles were imaged at 9.4 T
and contrasted with cells incubated with an equivalent concen-
tration of Gd-HPDO3A (Fig. 5A). The R1 for DNA-Gd@AuNP
labeled cells was signiﬁcantly (1.5x) higher than unlabeled cells
(p < 0.01) and Gd-HPDO3A-labeled cells (p < 0.05) (Fig. 5B). Gd-
HPDO3A labeling did not result in a signiﬁcant increase in R1compared to unlabeled cells. R2 was also signiﬁcantly (1.3x)
higher in DNA-Gd@AuNP labeled cells (p < 0.01) compared to
unlabeled cells, but did not differ signiﬁcantly from Gd-HPDO3A-
labeled cells (Fig. 5C). This is in contrast to the particle charac-
teristics in solution, where they affect R2 more strongly than R1,
and shows the importance of the microenvironment to MRI
detection.
Another important factor to consider is voxel size and the po-
tential for partial volume effects. Suspensions of unlabeled and
DNA-Gd@AuNP labeled cells were imaged at different cell densities
and voxel sizes (Fig. 6A). Larger voxels resulted in a higher signal-
to-noise ratio (SNR, i.e. gelatin to non-sample air), but even the
smallest voxel size resulted in an SNRof 13 (at 9.4 T). In comparison,
the R1 contrast (i.e. labeled versus unlabeled cells) was lower in
larger voxels due to a partial volume effect (Fig. 6B). An optimal
compromise to achieve both a high SNR and CNR can be achieved
with a voxel size of 32 nL, whereas a maximum 18% increase in R1
in vitro is achieved with a voxel size of 4 nL. A 4 nL voxel size hence
affords the detection of ~40 NSCs (¼ 1 104 cells/mL divided by 250
voxels of 4 nL present in 1 mL volume). A partial volume effect in cell
detection can potentially be mitigated by focusing the ROI on the
Fig. 4. Cellular effects ofDNA-Gd@AuNPs. Cells at day 0 and day 7 after labeling were stained with DAPI and Ki67 (A, scale bar ¼ 200 mm). No signiﬁcant effects were seen on the
number of surviving cells at any concentration of DNA-Gd@AuNPs at day 0 or day 7 (B) and this effect remained consistent when three separate batched of particles were tested (C).
The percentage of cells expressing Ki67 also remained consistent at all DNA-Gd@AuNP concentrations at day 0 and day 7 (D). Cells were also stained to assess phenotypic changes
(E), and no signiﬁcant differences were seen between those labeled at 20 nM nanoparticles and controls (F).
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labeled cells. Partial volume effects are predominantly present in
the corona, where voxels cover areas with increasingly smaller
fractions of labeled cells (Fig. 6C). Nevertheless, in vivo there is no
easily deﬁned ROI for detection and hence a smaller voxel volume is
the only option to avoid partial volume effects and detect labeled
cells. A clear T1 effect was observed here, although some attenua-
tion was evident due to intracellular incorporation with r1 relax-
ivity of DNA-Gd@AuNPs within cells being reduced to
3.87 mM1s1 (Fig. 6D) compared to 6.68 mM1s1 in solution (i.e.a 42% decrease).
3.6. In vivo detection of transplanted cells
To establish intracerebral detection of transplanted cells, cell
number and voxel size were arrayed and T1 maps were generated
to measure signal intensity changes due to labeled cells (Fig. 7A).
Very little change in T1 was evident at a large voxel size (195 nL),
whereas deposits of all 3 concentrations were readily identiﬁable at
a voxel size of 49 nL (at 9.4 T). The smaller voxel size of 7 nL
Fig. 5. In vitro imaging of cell pellets. Blank cells, and cells labeled either with Gd-HPDO3A or DNA-Gd@AuNP were imaged at 9.4 T to generate R1 and R2 maps (A). Cells labeled
with DNA-Gd@AuNP increased relaxivity compared to unlabeled cells and those labeled with Gd-HPDO3A on both R1 (B) and R2 (C).
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Importantly, the lowest concentration of cells (2.5  105 cells) was
more visible at this voxel size. To achieve a robust in vivo detection,
ideally a signal change of at least 25% is required. Using the acquired
array, a contour map was generated for the experimental space
(Fig. 7B). It is evident that there is some interaction between voxel
size and cell number on the T1 signal change. The aim of a 25%
change in T1 for a proof-of-principle study can be targeted with a
cell injection of 6.25 105 labeled cells and a voxel volume of 12 nL
(229 mm isotropic). This image resolution provides also a sufﬁcient
margin of error to achieve the required signal change with lower
concentrations of cells.
To validate the in vivoT1 detection of transplanted cells in a pilot
proof-of-principle study, three animals were transplanted with
both labeled (right hemisphere) and unlabeled cells (left hemi-
sphere). The deposit of labeled cells, as well as cells within the
injection tract, were readily distinguishable against the host brain
background on T1-weighted images in all animals at 9.4 T (Fig. 8A).
There was no evidence of a signal change in T1 caused by the un-
labeled cells in the homologous region in the opposite hemisphere.
A signal change of 17.7% was measured on the T1-weighted images
at the center of the deposit compared to non-labeled cells. To verify
that the signal change on the T1-weighted images was indeed due
to the transplanted cells, immunohistochemical analyses were
performed to detect human cells (HNA in green), as well as the Cy3
moiety of the DNA-Gd@AuNPs. Although human NSCs were pre-
sent in both hemispheres, only those containing DNA-Gd@AuNP
were detectable using the T1-weighted MR images. A higher
magniﬁcation image shows the center of a graft, where co-
localization of DNA-Gd@AuNP based on the Cy3 moiety can be
seen in human cells (Fig. 8B). Aggregates of gold nanoparticles can
seen as black spots. In order to assess whether the label may have
leaked from transplanted cells, the level of co-localization between
HNA and Cy3 was quantiﬁed (Fig. 8C).
Themajority of cells (71%) were correctly identiﬁed based on the
presence of DNA-Gd@AuNP, but there was a signiﬁcant (29%)
portion of false negatives (Type II error). However, there was verylittle transfer of agent with 0.38% host cells containing DNA-
Gd@AuNP (Type I error). DNA-Gd@AuNP therefore afford the
in vivo reliable detection of transplanted cells using T1-weighted
MR imaging with little risk of a Type I error (<5%), but signiﬁcantly
underestimating the total number of transplanted cells (Type II
error >20%).
4. Discussion
Achieving an unequivocal in vivo detection of transplanted cells
remains a major impediment to understand how the distribution of
therapeutic cells inﬂuences recovery. We here characterized the
use of a new class of MR contrast agents for cellular MRI that uses
gold nanoparticles as a platform to assemble multiple components
that afford visualization using different modalities, but with added
functionality, such as improved cellular uptake. These DNA-
Gd@AuNP were efﬁciently incorporated into cells without the use
of a transfection agent or electroporation to produce a high intra-
cellular yield of Gd(III) that preserved T1 relaxivity. At concentra-
tions up to 20 nM nanoparticles, no signiﬁcant effects on survival,
proliferation or differentiation were evident. Batch-to-batch vari-
ability was insigniﬁcant with good stability and retention of T1
relaxivity. Optimization of MR parameters indicated that voxel size
signiﬁcantly affects the degree of contrast, with smaller voxels
providing favorable conditions to detect small numbers of cells.
This approach allowed us to visualize transplanted cells using T1
contrast in vivo with veriﬁcation by immunohistochemistry indi-
cating a high level of speciﬁcity of the contrast (i.e. low Type I er-
ror), although there is a signiﬁcant underestimation of transplanted
cells using this approach (Type II error).
4.1. DNA-Gd@AuNP nanoparticle design facilitates T1 detection
The use of gold nanoparticles as platform to assemble multi-
functional and -modal nanoconstructs provides several opportu-
nities that improve on the polymeric conjugation of Gd(III)-
complexes [42]. Most notably, gold-based constructs can provide
Fig. 6. Effect of voxel size and ROI selection on cell detection in vitro. Labeled and unlabeled cells were suspended in 6% gelatin at different cell densities with T1 maps being
generated (A, þ ¼ labeled cells, ¡ ¼ blank cells). Increasing voxel size resulted in increased SNR, but less contrast between labeled and unlabeled cells (B). As voxel size increases,
peripheral voxels are increasingly susceptible to partial volume effects that attenuate T1 contrast (C). If measurement of T1 is conﬁned to the center of the ROI, there is little
attenuation of T1 contrast across voxel sizes, hence abating the partial volume effects. However, measurement of cell distribution will depend on a reliable measurement of pe-
ripheral voxels, as well as those at the core of the implantation site. The r1 relaxivity of DNA-Gd@AuNPs in cells is 3.87 mM1s1 (D), signiﬁcantly lower than that in solution.
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relaxivity of each monomer [24,28]. Grafting Gd(III) onto DNA-Au
nanoparticles here almost doubles the relaxivity of each Gd-
HPDO3A chelate demonstrating a key improvement in perfor-
mance compared to merely creating a polymeric compound. It is of
note that shape of particles is increasingly emerging as an impor-
tant design consideration in providing improvements in contrast
[34] that potentially will further improve relaxivity yield of each
Gd(III)-chelate, but might eventually also allow tuning to multiple
independent constructs being visualized using the same contrast
mechanism [43]. Conjugation of gadolinium chelates onto the gold
nanoparticles further affords an additional capping preventing
Gd(III) leaching, hence increasing their stability [44]. High ther-
mostability is essential to avoid ill-effects of Gd(III) ions on cellularhealth that could compromise long-term detection of transplanted
cells [45]. A further key performance characteristic of a putative
cellular MRI contrast agent is its reproducibility in manufacturing,
as well as relaxivity performance [4]. Indeed, the DNA-Gd@AuNP
nanoparticles here provided very consistent performance in phys-
ical characteristics, cell uptake, as well as relaxivity further sup-
porting their potential for cellular imaging studies.
Cell uptake into non-phagocytic cells, such as NSCs, remains a
major challenge to yield a sufﬁcient intracellular concentration that
affords T1 detection, but also to prevent a quenching of the T1 ef-
fect. Since the sensitivity of T1 based MR probes is inherently lower
than T2 agents [46], a higher concentration is required for detec-
tion. Nonspeciﬁc endocytosis or pinocytosis are the most
commonly used routes of agent uptake due to their simplicity and
Fig. 7. Effect of voxel size and cell number on ex vivo detection. T1 maps of 3 different injection sites were acquired at 6 different voxel sizes (A. Red arrows indicate implanted
cells). The difference in T1 between labeled and unlabeled cells was compared across cell number and voxel volume, with voxel volume having a more marked effect than cell
number. The conditions taken forward for in vivo image acquisition were 12 nL voxel volume (blue line) and 6.25  105 cells (red line, B). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
F.J. Nicholls et al. / Biomaterials 77 (2016) 291e306302efﬁciency. This typically results in localization of the agent to the
endosomes/lysosome pathway, leading to a quenching of the T1
effect above 1010 Gd/cell [12] and potentially a rapid clearancethrough exocytosis [47,48]. Instead of quenching of T2 relaxivity,
lysosome-entrapped agent creates susceptibility effects that favor
T2 detection [49] and can be used to track cells [45,50]. Indeed, the
Fig. 8. In vivo imaging with histological veriﬁcation. Three animals were transplanted with labeled cells in one hemisphere and unlabeled cells in the other. DNA-Gd@AuNP
labeled cells were clearly visible on T1-weighted (T1w) MR images (A). The deposit could be seen with some inﬁltration into the host tissue (inset for subject 1). In all animals
with labeled cells, the injection tract was clearly visible. In contrast, unlabeled cells did not produce a signal in the right hemisphere. Fluorescent histology corroborated these in vivo
results indicating that in both hemispheres transplanted cells were present (human nuclei antigen, HNA, in green), but only cells containing DNA-Gd@AuNP nanoparticles (as
detected by the red Cy3 moiety) produced a T1 effect on MR images. A higher magniﬁcation image shows good colocalisation of HNA and Cy3 (B, scale bar ¼ 100 mm), which is
supported by the quantiﬁcation showing a high level of accurate cell identiﬁcation with less than 1% of false positives, but a substantial number of false negatives (C). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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ever, upon incorporation into cells, this ratio is decreased due to the
R2 effect of cells. In contrast, there is less change in R1 between
solution and cells, hence the ratio of contrast of DNA-Gd@AuNP for
R1 improves upon cell internalization. Importantly, preservation of
T1 detection (not only increase in R1) is essential to provide an
unambiguous detection of labeled cells in contrast to T2-based ar-
tefacts, which could increase the in vivo error rate of cell imaging.
DNA-Gd@AuNP resulted in 108 Gd/cell, well below the threshold for
quenching and consequently resulted in a clear signal change on T1-
weighted images. The agent's microenvironment inﬂuences its
relaxivity properties, as it affects water diffusion and interaction
with the agent's outer sphere (i.e. chelate). This narrows the range
of optimal water exchange (tm) and tumbling rate (tr) for a given
ﬁeld [51]. As these molecular parameters are highly sensitive to
protein binding and water access, relaxivity in solution and inside
cells is signiﬁcantly different [49].
Here, cell incorporation led to a 42% loss of r1 relaxivity per
Gd(III) molecule. Nevertheless, incorporation of Gd(III) into DNA-
Gd@AuNP increased the relaxivity of each individual Gd(III)
chelate and resulted in an intracellular concentration that
permitted in vivo detection. Further improvements in relaxivity,
hence might afford a further reduction in required intracellular
Gd(III) or afford the detection of fewer cells. Alternatively, modiﬁ-
cation of the agent to reduce intracellular protein binding, for
instance, could preserve the relaxivity of DNA-Gd@AuNP in cells
and provide a dramatic improvement in cell detection [34].
4.2. Speciﬁcity of cell detection
Apart from the intracellular environment inﬂuencing the
relaxivity of DNA-Gd@AuNP, detection of cells is equally dependent
on the imaging volume within which these cells are embedded.
Partial volume effects are much discussed in the context of diffu-
sion weighted MRI [52], but little attention has been given to them
in the context of cell tracking [2,4]. To assess efﬁcacy of potential
cell transplant therapies and correlate cell presence and migration
with clinically relevant outcomes (such as motor coordination),
large animal numbers are required per study [53]. This necessitates
shorter imaging times per animal in order to increase throughput.
Lower resolution images are signiﬁcantly faster to acquire and have
a better SNR, but are likely to result in a partial volume effect that
leads to a signiﬁcant underestimation of the regional distribution of
cells. By arraying voxel size and cell number against T1 signal
change, a 12 nL voxel size (229 mm isotropic) here provided the
optimal intersection of these parameters for in vivo imaging.
Although these arrays indicate which parameters provide appro-
priate imaging conditions, it does not account for what spatial
resolution would be required to yield biologically important in-
formation. Unfortunately, at present it remains unknown what in-
formation would be relevant biologically to determine a
relationship between the distribution of transplanted cells and
their therapeutic efﬁcacy. Voxel size must therefore be based on a
balance between acceptable cell detection thresholds, imaging time
constraints, as well as the biological relevance of the information
gained from imaging.
Since there is normally very little contrast in a T1-weighted
image of the brain, T1 contrast agents are able to generate a very
speciﬁc signal that is less likely to be confused with naturally
occurring phenomena than T2 based agents [4]. However the
question of agent speciﬁcity to the cells remains an issue. Any
agent present outside transplanted cells, whether from the injec-
tate solution or after leakage from labeled cells, will be detected as
contrast. Bimodal agents allow validation of MRI contrast using
histology, as shown here and elsewhere [41,54,55], in order toassess the speciﬁcity of cell detection. One area of particular
concern is the fate of the label after cell death, as lingering label
could produce erroneous contrast [2,4]. However, there were very
few false positives, consistent with reports [16,56] indicating that
at least in the short-term there is little risk to overestimate the
implanted cells (i.e. Type I error is <5%). In contrast, there is a
signiﬁcant number of false negatives, approximately 30% which is
higher than what is typically acceptable for a Type II error (20%).
Although 100% of cells were labeled prior to injection with a slow
proliferation activity in NSCs, the exact source of the underesti-
mation remains unclear. It is conceivable that the ﬂuorescent
moiety is detaching and producing an underestimation of labeling
using this method of veriﬁcation. However, there is minimal loss
of Gd(III) complexes over two weeks, hence it is unlikely that the
ﬂuorescent moiety is detaching this rapidly. Gold nanoparticles
are known to eventually undergo a degradation process that leads
to their clearance [57], but they have an excellent stability proﬁle
[26].
5. Conclusions
We have shown that DNA-Gd@AuNPs have several advantages
for the visualization of cell transplants in the brain. Speciﬁcally,
these nanoconjugates provide an efﬁcient cellular uptake of large
quantities of Gd(III) into non-phagocytic NSCs, while preserving a
T1 contrast inside cells that affords an robust in vivo detection using
T1-weighted MR images. Conjugation of Gd(III) to Au nanoparticles
was essential to improve T1 relaxivity of Gd(III) molecules that was
attenuated upon intracellular uptake. Further engineering of par-
ticles is desirable to potentially further reduce this intracellular
attenuation of relaxivity, hence producing an even more efﬁcient
contrast agent for cell tracking. Long-term studies with larger
group size are nevertheless required to demonstrate the utility of
these agents to assess cell survival, as well as graft distribution.
Using DNA-Gd@AuNPs offers new opportunities to potentially
visualize transplanted cells unequivocally using T1 contrast and use
cellular MRI as a tool to derive biologically relevant information
that allows us to understand how the survival and location of
implanted cells determines therapeutic efﬁcacy.
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